Please enter keyword
Please enter keyword
Introduction of Biocytogen Animal Centers
Since 2014, Biocytogen has been operating three animal centers distributed in Nantong (Jiangsu, P.R.China), Daxing (Beijing, P.R.China), and Boston (USA) under the brand of "Biocytogen Animals". The ultimate goal is to provide superior supports to global customers for their scientific research as well as new drug discovery using our innovative genetically engineered models (GEMs). Through implementing strict, scientific, and standard operating procedures, and a highly efficient facility management system, the animal centers have performed the same or even higher standards for critical quality-control testing to identify microbial contamination. With innovative animal models, high standard quality-control program, and tailored services, the animal centers have contributed significant shares of Biocytogen to support and promote the rapid growth of the biopharma industry throughout the world.
Animal/Cell Models
MNC Cooperation
AAALAC Certification
Animal Center
AAALAC certificate
Laboratory animal productio...
Laboratory animal use permi...
New high-tech enterprise
Animal export qualification
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMiceTM licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit